Current Management of Patients With Invasive Cervical Carcinoma
Authors:
- Perry W. GrigsbyPGPerry W. Grigsby
- Thomas J. HerzogTHThomas J. Herzog
- 1 September 2001
- journal article
- review article
- Published by Wolters Kluwer Health in Clinical Obstetrics and Gynecology
- Vol. 44 (3) , 531-537
Abstract
After the logic of evidence-based medicine, there are several conclusions to be reached from these recent prospective, randomized phase III clinical trials. Patients with stages IB2 and IIA cervical carcinoma, although technically manageable, should be treated with external pelvic irradiation and brachytherapy and weekly (cisplatin 40 mg/m2 x 6 wk), if it is suspected that the likelihood of positive lymph nodes or margins requiring adjuvant treatment after radical surgery would be significant. In those patients in whom the risks of either positive margins or lymph nodes are low, either radical surgery or radiation are equally efficacious options. A recent report that surveyed the Surveillance, Epidemiology, and End Results program database suggested that there may be a survival advantage for surgical intent-to-treat patients compared with the radiation intent-to-treat patients for tumors 4 cm or smaller in patients with stage IB and IIA cervical cancers. Certainly, toxicity criteria for these patients in terms of long-term problems need to be further examined. For those patients who undergo a radical hysterectomy and lymph node dissection, postoperative irradiation is indicated if high-risk factors such as large tumor size, lymph vascular space invasion, and deep stromal invasion are identified. Patients who are found to have positive lymph nodes, positive parametrial invasion, or positive margins at the time of hysterectomy should receive postoperative irradiation with chemotherapy. All other patients with more advanced clinical stages of cervical carcinoma should be treated with external pelvic irradiation, brachytherapy, and concurrent chemotherapy. Based on the results of the randomized studies, there appears to be no role for either hydroxyurea or fluorouracil. The chemotherapy agent of choice, at present, is cisplatin administered concurrently with irradiation at a dose of 40 mg/m2 weekly for 6 weeks. Concurrent chemotherapy should be avoided in patients with a poor performance status and other severe comorbidities, and these patients should be treated with irradiation alone. Further refinement of treatment for those patients who require combined chemo/radiation versus those with comorbidities such that combination chemotherapy is actually too toxic must be defined.Keywords
This publication has 14 references indexed in Scilit:
- New approaches in the surgical management of early stage cervical cancerCurrent Opinion in Obstetrics and Gynecology, 2001
- Type II Radical Hysterectomy: Evaluating Its Role in Cervical CancerGynecologic Oncology, 2001
- Class II versus Class III Radical Hysterectomy in Stage IB–IIA Cervical Cancer: A Prospective Randomized StudyGynecologic Oncology, 2001
- Laparoscopic Assessment of the Sentinel Lymph Node in Early Stage Cervical CancerGynecologic Oncology, 2000
- Intraoperative Lymphatic Mapping in Cervix Cancer Patients Undergoing Radical Hysterectomy: A Pilot StudyGynecologic Oncology, 2000
- Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the CervixJournal of Clinical Oncology, 2000
- A Randomized Trial of Pelvic Radiation Therapy versus No Further Therapy in Selected Patients with Stage IB Carcinoma of the Cervix after Radical Hysterectomy and Pelvic Lymphadenectomy: A Gynecologic Oncology Group StudyGynecologic Oncology, 1999
- Cisplatin, Radiation, and Adjuvant Hysterectomy Compared with Radiation and Adjuvant Hysterectomy for Bulky Stage IB Cervical CarcinomaNew England Journal of Medicine, 1999
- Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancerThe Lancet, 1997
- Prophylactic Extended-Field Irradiation of Para-aortic Lymph Nodes in Stages IIB and Bulky IB and IIA Cervical CarcinomasJAMA, 1995